TNF and inflammatory bowel disease: Most of the patients with IBD were being treated with biologic agents targeting TNF (infliximab, adalimumab, or golimumab) alone, although some were receiving a blocker of IL-12/23 (ustekinumab), α4β7 integrin (vedolizumab), or combination therapy with an immunomodulator (Table 1).